一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

Welcome to chemicalbook!
Chinese English Japanese Germany Korea
010-86108875
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook CAS DataBase List Fostamatinib
901119-35-5

Fostamatinib synthesis

2synthesis methods
Fostamatinib, also known as R 788 and R-935788, is an orally active, potent and selective Syk kinase inhibitor with potential anti-inflammatory and immunomodulating activities. Fostamatinib is also a pro-drug of R-406. Fostamatinib inhibits Syk kinase-mediated IgG Fc gamma receptor signaling, resulting in inhibition of the activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage.
Synthetic Routes
  • ROUTE 1
  • 202112079991811245.jpg

    Felfer, Ulfried; Giselbrecht, Karl-Heinz; Wolberg, Michael. Synthesis of N4-(2,2-dimethyl-4-[(dihydrogen phosphonoxy)-3-oxo-5-pyrido[1,4]oxazin-6-yl]-5-fluoro-N2-(3,4,5-trimethoxyphenyl))-2,4-pyrimidinediamine disodium salt. Assignee Rigel Pharmaceuticals, Inc., USA. WO 2011002999. (2011).

  • ROUTE 2
  • 202112073697567709.jpg

    1. Grossbard, Elliott; Argade, Ankush; Singh, Rajinder; Hitoshi, Yasumichi. (Assignee Rigel Pharmaceuticals, Inc., USA). Preparation of pyrimidine-2,4-diamines as RET kinase inhibitors for treatment of cell proliferative disorders. WO 2009003136. 2. Argade, Ankush; Bhamidipati, Somasekhar; Li, Hui; Sylvain, Catherine; Clough, Jeffrey; Carroll, David; Keim, Holger; Braselmann, Sylvia; Taylor, Vanessa; Zhao, Haoran; Herlaar, Ellen; Issakani, Sarkiz D.; Wong, Brian R.; Masuda, Esteban S.; Payan, Donald G.; Singh, Rajinder. Design, synthesis of diaminopyrimidine inhibitors targeting IgE- and IgG-mediated activation of Fc receptor signaling. Bioorg. & Med. Chem. Lett. 2015, 25(10), 2122-2128

202112079991811245.jpg

Felfer, Ulfried; Giselbrecht, Karl-Heinz; Wolberg, Michael. Synthesis of N4-(2,2-dimethyl-4-[(dihydrogen phosphonoxy)-3-oxo-5-pyrido[1,4]oxazin-6-yl]-5-fluoro-N2-(3,4,5-trimethoxyphenyl))-2,4-pyrimidinediamine disodium salt. Assignee Rigel Pharmaceuticals, Inc., USA. WO 2011002999. (2011).

-

Yield:901119-35-5 100%

Reaction Conditions:

with acetic acid in water at 65; for 3 h;

Steps:

1 Synthesis of N4-(2,2-dimethyl-4-[(dihydrogen phosphonoxy)methyl]-3-oxo-5- pyrido[1,4]oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine (Compound 4)
N4-(2,2-dimethyl-4-[(di-tert-butyl phosphonoxy)methyl]-3-oxo-5-pyrido[1,4]oxazin-6-yl)- 5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine (Compound 3); (15.0 g, 21.67 mmol) dissolved in AcOH:H20 (225 mL, 4:1) was heated at 650C (oil bath temp). The progress of the reaction was monitored by in process LC/MS. The reaction mixture transformed to faint tan white solid after 1h of heating. At this point most of Compound 3 converted to mono des t-butyl product. After 3h of heating, consumption of SM and complete conversion of intermediate (mono des t- butylated) to product was observed. Reaction mixture was cooled, poured onto ice-water (200 mL), stirred for 20 min and filtered. The clear white filter cake was washed with water (600 ml) and acetone (200 mL) successively, dried for 2h followed by drying under high vacuum over P2O5 in a desiccator. Weight of the solid: 12.70 g; purity: 97% (Compound 3) and 3% (Compound 1) 1H NMR indicated acetic acid presence (1:1) To remove acetic acid, the solid was taken in acetonitrile (300 mL) and concentrated by rotovap vacuum. This process was repeated 2 times with acetonitrile and toluene (3 X 300 mL). The solid obtained was dried under high vacuum at 500C. Finally, the solid was taken in acetone (400 mL), filtered and dried to provide N4-(2,2- dimethyl-4-[(dihydrogen phosphonoxy)methyl]-3-oxo-5-pyrido[1,4]oxazin-6-yl)-5-fluoro-N2- (3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine (Compound 4). 1H NMR (DMSO-d6): d 9.21 (br s, 2H), 8.16 (d, 1H, J = 2.6 Hz), 7.93 (d, 1H, J = 8.5 Hz), 7.39 (d, 1H, J = 8.5 Hz), 7.05 (s, 2H), 5.79 (d, 1H, J3PH = 6.6 Hz), 3.67 (s, 6H), 3.59 (s, 3H), 1.44 (s, 6H). LCMS: ret. time: 8.52 min.; purity: 95%; MS (m/e): 581 (MH+).31P NMR (DMSO-d6): -2.17.

References:

RIGEL PHARMACEUTICALS, INC. WO2021/30526, 2021, A1 Location in patent:Page/Page column 40-41

FullText

Fostamatinib Related Search:

乐山市| 讷河市| 香港| 达日县| 临安市| 肥西县| 汝南县| 文登市| 灌云县| 中阳县| 观塘区| 若羌县| 织金县| 张家界市| 平舆县| 库尔勒市| 阿克| 宁南县| 六安市| 满城县| 中宁县| 揭西县| 泰顺县| 邯郸县| 南充市| 常州市| 嵩明县| 凤阳县| 毕节市| 徐州市| 宣威市| 东乡族自治县| 益阳市| 正蓝旗| 嘉禾县| 吴江市| 资兴市| 诸城市| 拜城县| 长兴县| 比如县|